文献速递肝病消化道肿瘤与早癌

丙型肝炎相关肝细胞癌参保患者直接抗病毒药物治疗率及治疗相关因素:一项真实世界全国性研究

Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-11-08

该回顾性研究基于Optum's Clinformatics® Data Mart数据库,纳入2015年1月至2021年3月3922例丙型肝炎相关肝细胞癌参保患者,仅922例(23.5%)接受直接抗病毒药物(DAA)治疗。接受DAA治疗与较年轻年龄、消化内科/感染科医生诊疗及肝硬化相关,且与未治疗者相比5年生存率更高(47.2% vs 35.2%)。

要点

  • 丙型肝炎相关肝细胞癌参保患者中仅23.5%接受DAA治疗。
  • 消化内科/感染科医生诊疗与接受DAA治疗相关(HR 3.06)。
  • DAA治疗与较低死亡率相关(aHR 0.61)。

核心结论

  • DAA治疗在丙型肝炎相关肝细胞癌参保患者中仍未充分利用,不足四分之一患者接受治疗。
  • 消化内科/感染科医生诊疗和失代偿期肝硬化是DAA治疗的预测因素;需要额外努力来提高对丙型肝炎治疗的认识。

研究设计与样本

  • 回顾性研究,时间范围为2015年1月至2021年3月。
  • 使用Optum's Clinformatics® Data Mart数据库,纳入全国样本的丙型肝炎相关肝细胞癌参保患者,共3922例。

主要发现

  • 3922例丙型肝炎相关肝细胞癌患者中,922例(23.5%)接受DAA治疗。
  • 与未治疗患者相比,接受DAA治疗的患者更年轻(65.2 ± 7.5岁 vs 66.4 ± 7.5岁,p < 0.001),更常就诊于消化内科/感染科医生(41.2% vs 34.2%),且失代偿期肝硬化比例更高(56% vs 53%,p = 0.001)。
  • 多因素分析显示,较年轻年龄(HR: 0.98,95% CI: 0.97-0.99,p < 0.001)、消化内科/感染科医生诊疗(HR: 3.06,95% CI: 2.13-4.51,p < 0.001)以及肝硬化(代偿期:HR: 1.60,95% CI: 1.18-2.21,p = 0.003;失代偿期:HR: 1.45,95% CI: 1.07-1.98,p = 0.02)与接受DAA治疗相关,而性别、种族或民族无显著关联。
  • 接受DAA治疗的患者5年生存率显著高于未治疗患者(47.2% vs 35.2%,p < 0.001)。
  • 在调整年龄、性别、种族/民族、Charlson合并症指数和肝细胞癌治疗后,接受DAA治疗与较低死亡率相关(aHR: 0.61,95% CI: 0.53-0.69,p < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since the inception of the interferon-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection, guidelines as to who should receive this potentially curative treatment have evolved. Treatment with DAAs is now considered for all patients except for those considered moribund. AIM: To determine the DAA treatment rate for patients with HCV-related hepatocellular carcinoma (HCC). METHODS: This was a retrospective study from January 2015 to March 2021 of a national sample of privately insured patients with HCV-related HCC using Optum's Clinformatics® Data Mart (CDM) Database - a large, de-identified, adjudicated claims database. RESULTS: We identified 3922 patients with HCV-related HCC: 922 (23.5%) received DAA. Compared to untreated patients, DAA-treated patients were younger (65.2 ± 7.5 vs. 66.4 ± 7.5 years, p < 0.001), more frequently saw a gastroenterology/infectious disease (GI/ID) physician (41.2% vs. 34.2%), and had decompensated cirrhosis (56% vs. 53%, p = 0.001). In multivariable analysis, younger age (HR: 0.98, 95% CI: 0.97-0.99, p < 0.001), GI/ID care (HR: 3.06, 95% CI: 2.13-4.51, p < 0.001), and having cirrhosis (compensated: HR: 1.60, 95% CI: 1.18-2.21, p = 0.003; decompensated: HR: 1.45, 95% CI: 1.07-1.98, p = 0.02) were associated with receiving DAA treatment, but not sex, race, or ethnicity. DAA-treated patients had significantly higher 5-year survival than untreated patients (47.2% vs. 35.2%, p < 0.001). Following adjustment for age, sex, race/ethnicity, Charlson Comorbidity Index, and HCC treatment, receiving DAA treatment was associated with lower mortality (aHR: 0.61, 95% CI: 0.53-0.69, p < 0.001). CONCLUSION: DAA treatment remains underutilised in insured patients with HCV-related HCC; fewer than one in four patients received treatment. Seeing a specialist and having decompensated cirrhosis were predictors for DAA treatment; additional efforts are needed to increase awareness of HCV treatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kam LY, Yeo YH, Ji F, et al. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study. Aliment Pharmacol Ther. 2023. PMID: 37937485. doi:10.1111/apt.17794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。